Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan
· Delayed Price · Currency is TWD 220.50
-3.50 (-1.56%)
Apr 29, 2026, 1:30 PM CST
Lotus Pharmaceutical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 57,950 | 74,423 | 71,524 | 71,935 | 64,462 | 25,569 | Upgrade
|
| Market Cap Growth | -1.63% | 4.05% | -0.57% | 11.59% | 152.11% | 30.27% | Upgrade
|
| Enterprise Value | 97,686 | 81,170 | 80,276 | 81,666 | 71,660 | 30,851 | Upgrade
|
| Last Close Price | 220.50 | 283.00 | 262.47 | 260.17 | 232.56 | 90.84 | Upgrade
|
| PE Ratio | 12.22 | 15.77 | 14.12 | 17.52 | 21.34 | 18.22 | Upgrade
|
| Forward PE | 13.67 | 11.05 | 12.05 | 15.36 | 18.39 | 15.41 | Upgrade
|
| PS Ratio | 2.83 | 3.63 | 3.85 | 4.24 | 4.41 | 2.02 | Upgrade
|
| PB Ratio | 2.44 | 3.13 | 3.38 | 4.15 | 4.65 | 2.31 | Upgrade
|
| P/TBV Ratio | - | - | 7.26 | 11.65 | 28.14 | 10.18 | Upgrade
|
| P/FCF Ratio | 9.40 | 12.08 | 12.33 | 59.77 | 20.52 | - | Upgrade
|
| P/OCF Ratio | 7.75 | 9.95 | 11.62 | 44.56 | 17.33 | 213.68 | Upgrade
|
| EV/Sales Ratio | 4.76 | 3.96 | 4.32 | 4.82 | 4.90 | 2.44 | Upgrade
|
| EV/EBITDA Ratio | 12.63 | 10.67 | 10.95 | 13.23 | 14.07 | 9.63 | Upgrade
|
| EV/EBIT Ratio | 15.74 | 13.08 | 12.99 | 16.07 | 16.86 | 12.20 | Upgrade
|
| EV/FCF Ratio | 15.85 | 13.17 | 13.84 | 67.85 | 22.81 | - | Upgrade
|
| Debt / Equity Ratio | 2.00 | 2.00 | 0.65 | 0.67 | 0.64 | 0.63 | Upgrade
|
| Debt / EBITDA Ratio | 6.14 | 6.14 | 1.83 | 1.84 | 1.72 | 2.12 | Upgrade
|
| Debt / FCF Ratio | 7.70 | 7.70 | 2.36 | 9.63 | 2.84 | - | Upgrade
|
| Net Debt / Equity Ratio | 1.67 | 1.67 | 0.36 | 0.57 | 0.50 | 0.48 | Upgrade
|
| Net Debt / EBITDA Ratio | 5.22 | 5.22 | 1.04 | 1.59 | 1.36 | 1.67 | Upgrade
|
| Net Debt / FCF Ratio | 6.45 | 6.45 | 1.32 | 8.15 | 2.21 | -11.78 | Upgrade
|
| Asset Turnover | 0.28 | 0.28 | 0.51 | 0.54 | 0.58 | 0.62 | Upgrade
|
| Inventory Turnover | 1.28 | 1.28 | 2.01 | 2.13 | 2.13 | 2.65 | Upgrade
|
| Quick Ratio | 0.92 | 0.92 | 1.63 | 1.85 | 1.17 | 1.16 | Upgrade
|
| Current Ratio | 1.57 | 1.57 | 2.15 | 2.80 | 1.81 | 1.93 | Upgrade
|
| Return on Equity (ROE) | 21.00% | 21.00% | 26.30% | 26.32% | 24.23% | 14.16% | Upgrade
|
| Return on Assets (ROA) | 5.30% | 5.30% | 10.57% | 10.16% | 10.47% | 7.71% | Upgrade
|
| Return on Invested Capital (ROIC) | 11.09% | 11.10% | 17.59% | 17.05% | 17.51% | 12.44% | Upgrade
|
| Return on Capital Employed (ROCE) | 7.00% | 7.00% | 19.50% | 17.90% | 18.00% | 15.00% | Upgrade
|
| Earnings Yield | 8.15% | 6.34% | 7.08% | 5.71% | 4.69% | 5.49% | Upgrade
|
| FCF Yield | 10.63% | 8.28% | 8.11% | 1.67% | 4.88% | -1.77% | Upgrade
|
| Dividend Yield | 1.14% | 0.91% | 2.18% | 1.79% | 1.49% | 2.13% | Upgrade
|
| Payout Ratio | 32.20% | 32.20% | 24.32% | 22.07% | 16.75% | 6.56% | Upgrade
|
| Buyback Yield / Dilution | 0.67% | 0.67% | -0.53% | -0.13% | -1.95% | -5.43% | Upgrade
|
| Total Shareholder Return | 1.83% | 1.57% | 1.66% | 1.66% | -0.46% | -3.30% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.